XML 20 R4.htm IDEA: XBRL DOCUMENT v3.23.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Grant revenue $ 0     $ 0 $ 0 $ 81,526 $ 81,526 $ 385,501
Operating expenses:                
Research and development 6,947,979     2,721,196 14,486,896 5,358,917 9,123,479 15,554,171
General and administrative 1,651,775     1,249,337 4,562,293 3,363,672 4,986,611 3,577,153
Total operating expenses 8,599,754     3,970,533 19,049,189 8,722,589 14,110,090 19,131,324
Loss from operations (8,599,754)     (3,970,533) (19,049,189) (8,641,063) (14,028,564) (18,745,823)
Other income:                
Interest income 190,936     2,431 674,835 3,747 7,439 4,736
Net loss $ (8,408,818) $ (5,927,620) $ (4,037,916) $ (3,968,102) $ (18,374,354) $ (8,637,316) $ (14,021,125) $ (18,570,317)
Basic and diluted:                
Net loss per common share (in dollars per share) $ (0.32)     $ (0.17) $ (0.69) $ (0.63) $ (0.83) $ (3.04)
Weighted average shares outstanding (in shares) 26,544,058     23,461,665 26,442,847 13,818,315 16,973,194 6,099,933